SALARIUS PHARMACEUTICALS INC (SLRX) Stock Analyst Earnings Estimates
NASDAQ:SLRX - Nasdaq - US79400X4043 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.47M 313.10% | 5.23M 50.72% | 1.84M -64.82% | -100.00% | 12.113M | ||||
| EBITDA YoY % growth | -8.14M 60.23% | -7.77M 4.55% | -12.79M -64.61% | N/A -79.52% | N/A 43.88% | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.27M 60.05% | -7.79M 5.80% | -12.81M -64.44% | -22.734M -79.31% | -18.21M 43.86% | -6.242M 51.59% | -6.25M -0.11% | N/A | |
| Operating Margin | -238.33% | -148.95% | -696.20% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -110.00 72.77% | -60.00 45.45% | -60.75 -44.00% | -5.25 93.92% | -4.12 21.55% | -9.35 -126.98% | -4.39 53.11% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -6.84 -564.36% | -5.97 -81.92% | -5.97 89.09% | -6.01 -690.50% | -6.01 12.22% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.76 85.38% | -2.45 | 1.69 | 68.95% |
| Q2 2024 Q2Q % growth | -377.90% | -54.67 | % | |
| Q1 2024 Q2Q % growth | -3.28 81.61% | -54.67 | 51.39 | 94.00% |
| Q4 2023 Q2Q % growth | 95.45% | -1.03 | % | |
| Q3 2023 Q2Q % growth | -5.20 73.68% | -9.79 | 4.59 | 46.90% |
| Q2 2023 Q2Q % growth | -11.44 36.44% | -10.58 | -0.86 | -8.12% |
| Q1 2023 Q2Q % growth | -17.84 31.38% | -20.40 | 2.56 | 12.55% |
| Q4 2022 Q2Q % growth | -22.64 -25.78% | -17.58 | -5.06 | -28.75% |
| Q3 2022 Q2Q % growth | -19.76 -23.50% | -20.81 | 1.05 | 5.04% |
| Q2 2022 Q2Q % growth | -18.00 -28.57% | -21.42 | 3.42 | 15.97% |
| Q1 2022 Q2Q % growth | -26.00 -116.67% | -18.36 | -7.64 | -41.61% |
| Q4 2021 Q2Q % growth | -18.00 10.00% | -17.34 | -0.66 | -3.81% |
| Q3 2021 Q2Q % growth | -16.00 20.00% | -13.26 | -2.74 | -20.66% |
| Q2 2021 Q2Q % growth | -14.00 46.15% | -11.56 | -2.44 | -21.10% |
| Q1 2021 Q2Q % growth | -12.00 72.73% | -11.22 | -0.78 | -6.95% |
| Q4 2020 Q2Q % growth | -20.00 | -22.44 | 2.44 | 10.87% |
| Q3 2020 Q2Q % growth | -20.00 | -21.42 | 1.42 | 6.63% |
| Q2 2020 Q2Q % growth | -26.00 | -33.66 | 7.66 | 22.76% |
| Q1 2020 Q2Q % growth | -44.00 | -89.76 | 45.76 | 50.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2022 Q2Q % growth | -100.00% | % | ||
| Q4 2021 Q2Q % growth | -100.00% | 441.997K | -441.997K | -100.00% |
| Q3 2021 Q2Q % growth | -100.00% | 1.182M | -1.182M | -100.00% |
| Q2 2021 Q2Q % growth | 570K -54.03% | 1.305M | -735K | -56.32% |
| Q1 2021 Q2Q % growth | 1.27M 12.39% | 1.397M | -127K | -9.09% |
| Q4 2020 Q2Q % growth | 1.48M 42.31% | 1.507M | -27K | -1.79% |
| Q3 2020 Q2Q % growth | 1.38M 58.62% | 1.37M | 10K | 0.73% |
| Q2 2020 Q2Q % growth | 1.24M 37.78% | 1.217M | 23K | 1.89% |
| Q1 2020 Q2Q % growth | 1.13M 71.21% | 1.414M | -284K | -20.08% |
| Q4 2019 Q2Q % growth | 1.04M | 3.37M | -2.33M | -69.14% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |